CMRX
Chimerix, Inc.
Set alert
52-week range unavailable
- YTD
- +145.40%
- 1 year
- +844.69%
- Open
- 8.54
- Prev close
- 8.54
- Mkt cap
- 271.61M
- Vol
- 2.55M
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.54
- High
- 8.54
- Forward P/E
- -2.93
- Beta
- 1.13
- Short ratio
- 2.44
- Inst. own
- 45.90%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.26
- 200-d avg
- 1.02
- 1y target
- 8.40
Key statistics
- Market cap
- 271.61M
- Enterprise value
- 133.32M
- Trailing P/E
- 0.00
- Forward P/E
- -2.93
- PEG ratio
- 0.00
- Price / sales
- 1708.22
- Price / book
- 2.00
- EPS (TTM)
- -0.94
- Beta
- 1.13
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 159.00K
- Revenue growth
- 136.40%
- Free cash flow
- -40.05M
- Total cash
- 136.23M
- Total debt
- 644.00K
- Return on equity
- -48.59%
- Shares outstanding
- 89.94M
- Short % of float
- 0.76%
- 50-day average
- 1.26
- 200-day average
- 1.02
Analyst view
Consensus: strong buy
- Target (low)
- 6.00
- Target (mean)
- 8.40
- Target (high)
- 11.00
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.275.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.24 | -0.26 | -0.02 | -8.33% |
| Aug 13, 2024 | Jun 1, 2024 | -0.23 | -0.23 | 0.00 | 0.00% |
| May 1, 2024 | Mar 1, 2024 | -0.21 | -0.25 | -0.04 | -19.05% |
| Feb 29, 2024 | Dec 1, 2023 | -0.23 | -0.20 | +0.03 | +13.04% |
| Nov 2, 2023 | Sep 1, 2023 | -0.22 | -0.27 | -0.05 | -22.73% |
| Aug 3, 2023 | Jun 1, 2023 | -0.23 | -0.21 | +0.02 | +8.70% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | Wedbush | reit | Outperform | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Mar 1, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 17, 2023 | Wedbush | reit | Outperform | Outperform |
About Chimerix, Inc.
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- chimerix.com
News
- Jazz Pharmaceuticals Completes Acquisition of Chimerix
- Top 3 Health Care Stocks That May Crash In Q2
- Biotech Stocks Q1 2025 Recap: Winners And Underperformers
- Chimerix Reports Fourth Quarter and Year End 2024 Financial Results
- CHIMERIX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chimerix, Inc. - CMRX
- Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- CMRX Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Chimerix, Inc. is Fair to Shareholders
- The Zacks Analyst Blog Jazz Pharmaceuticals, Chimerix, Moderna, GSK and Regeneron Pharmaceuticals
- Biotech Stocks Roundup: CMRX Up on JAZZ Bid, MRNA Up on Updates & More
- Jazz Offers to Buy Chimerix for $935M to Boost Oncology Portfolio
Your note
Sign in to keep a note on CMRX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ALRUTZ MICHAEL ALBERT | General Counsel | Stock Award(Grant) | Jan 31, 2024 | 168,098 |
| ANDRIOLE MICHAEL T. | Chief Executive Officer | Sale | Aug 7, 2024 | 462,453 |
| DEMSKI MARTHA J. | Director | Purchase | May 9, 2023 | 0 |
| JAKEMAN DAVID A | Officer | Sale | Feb 13, 2024 | 141,232 |
| LASPALUTO MICHELLE | Chief Financial Officer | Sale | Feb 13, 2024 | 110,999 |
| MELEMED ALLEN S | Officer | Stock Award(Grant) | Jan 31, 2024 | 86,430 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 9.78% | 8,800,000 | 26.58M | Sep 29, 2024 |
| Vanguard Group Inc | 4.81% | 4,330,398 | 13.08M | Sep 29, 2024 |
| Monaco Asset Management SAM | 4.69% | 4,221,574 | 12.75M | Sep 29, 2024 |
| Millennium Management Llc | 2.66% | 2,395,735 | 7.24M | Sep 29, 2024 |
| Armistice Capital, LLC | 2.46% | 2,208,000 | 6.67M | Sep 29, 2024 |
| Acadian Asset Management. LLC | 2.43% | 2,188,482 | 6.61M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.23% | 2,904,360 | 8.77M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.46% | 1,308,906 | 3.95M | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Fund | 0.96% | 860,124 | 2.60M | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 415,735 | 1.26M | Oct 30, 2024 |
| Northern Small Cap Value Fund | 0.39% | 348,177 | 1.05M | Sep 29, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.23% | 205,790 | 621.49K | Sep 29, 2024 |